hypertrophy, which is commonly seen in obesity and type 2 diabetes and is associated with mitochondrial dysfunction and lipotoxicity 4, 5 , remain largely unknown. Here we took advantage of the recent step changes in integrative systems genetics approaches in the rat 6, 7 to dissect a bloodpressure-independent cardiac mass quantitative trait locus (QTL) and to identify the causative gene and underlying mechanism.
The rat is unique for the study of cardiac mass, with more than 75 QTLs identified for this trait (Rat Genome Database; http://rgd. mcw.edu/). Rat chromosome 3p (0-25 megabase pairs (Mbp)) contains a highly replicated and blood-pressure-independent QTL for cardiac mass, which has been mapped in crosses of the spontaneously hypertensive rat (SHR) or the SHR stroke prone (SHRSP) rat to Wistar Kyoto (WKY) or salt sensitive (SS) rats 13, 14 . To dissect this locus genetically, we generated an F 2 intercross of SHR and Brown Norway (BN) strains and further replicated the LVM QTL (logarithm of odds (LOD) 5 4.2) ( Fig. 1a) . We confirmed the blood-pressure-independent QTL effect in a congenic strain (SHR.BN-(3L)) that had a lower LVM and smaller cardiomyocytes than the SHR strain ( Fig. 1b, c) , and we refined the QTL region (to chromosome 3, 6.4-11.2 Mbp) using a second congenic strain (SHR.BN-(3S)) ( Supplementary Fig. 1 ). In the F 2 cross, in the SHR.BN-(3L) strain and in previous experimental crosses 13, 14 , the SHR allele at the locus was associated with increased cardiac mass, and this effect was blood pressure independent ( Fig. 1a, b, d) . Functional assessment in vivo revealed that the SHR.BN-(3L) strain had better cardiac performance at baseline and after stimulation, compared with the SHR strain ( Supplementary Fig. 1 ). These data show that an SHR allele at the cardiac mass QTL on rat chromosome 3p increases LVM and adversely affects cardiac function.
We used the new genotypes generated in our F 2 cross and those from previous experiments 13, 14 to refine the QTL region, and we identified five distinct loci (spanning 750 kilobase pairs in total) that cosegregated with the haplotypes associated with LVM variation (Fig. 1e) . Endog, which we had previously shown to be cis regulated in the heart (P 5 3 3 10 26 ) 7 , was the only gene at these loci that was differentially regulated in a consistent direction in the SHR and SHRSP hearts compared with the WKY heart ( Supplementary Table 1 ). ENDOG is a nuclear-encoded, mitochondria-localized nuclease with a proposed but disputed function in apoptosis 8, [15] [16] [17] and no known effect on cardiac mass or function. We observed reduced expression of Endog transcripts and lack of ENDOG protein in all strains that had increased cardiac mass ( Fig. 1f , g). Sequencing of Endog revealed promoter and coding sequence variation, and we identified an SHRspecific, frame-shift-causing insertion in exon 1 of Endog that was associated with increased heart weight and LVM ( Supplementary  Fig. 2 ). There was a marked reduction in cardiac nuclease activity, which was ENDOG dependent 18 , in the SHR heart compared with the BN heart ( Fig. 1h , i). In recombinant inbred strains derived from the SHR and BN strains 6, 7 , we confirmed the direct relationship between the insertion in SHR and the lack of nuclease activity ( Fig. 1j ), and we mapped Endog-dependent nuclease activity to a single locus that encodes Endog (Fig. 1k ). These data identify Endog as the candidate gene at the QTL and implicate Endog loss of function as the mechanism for increased cardiac mass and impaired heart function.
We performed immunoblotting across rat and mouse tissues and determined that ENDOG was most highly expressed in the heart, where it was localized to cardiomyocytes ( Fig. 2a, b ) and co-localized with mitochondria ( Supplementary Fig. 3 ). Using a short hairpin RNA (shRNA) knockdown of Endog (shEndog) 19 , we tested the effect of Endog loss of function in cardiomyocytes and observed an increase in hypertrophic biomarkers and cell size in the absence of pro-hypertrophic stimulation ( Fig. 2c, d) . Conventional blood-pressure-dependent hypertrophic signalling pathways 12 were not activated in shEndogtreated cells, but AMP-activated protein kinase (AMPK) was activated ( Supplementary Fig. 4 ), which can induce cardiac hypertrophy 20 . We also observed increased amounts of reactive oxygen species (ROS), which are also pro-hypertrophic stimuli 21 that act through multiple downstream effectors ( Supplementary Fig. 4 ). These data show that Endog loss of function directly induces cardiomyocyte hypertrophy in vitro and that this hypertrophy is associated with the activation of two Relative myocyte size
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pro-hypertrophic pathways, both of which have previously been linked to mitochondrial dysfunction [20] [21] [22] . We then examined the effects of Endog loss of function in vivo in the Endog-deleted (Endog 2/2 ) mouse 17 , which shows no detectable difference in apoptotic phenotypes compared with wild-type mice, an observation that was confirmed in an independent Endog-deleted strain 16 . Compared with controls, Endog 2/2 mice had larger cardiomyocytes at baseline ( Fig. 2e ) in the absence of stimulation, in keeping with our observations in the SHR.BN-(3L) rat ( Fig. 1c ) and in vitro ( Fig. 2c ). Following angiotensin-II-mediated stimulation of hypertrophy, which is largely ROS dependent 21 , we observed an increase in cardiomyocyte size, hypertrophic biomarker expression and LVM in Endog 2/2 mice ( Fig. 2e, f and Supplementary Fig. 5 ). Endog 2/2 mice had blood pressures that were equivalent to those of control mice at baseline (P 5 0.49) and after stimulation with angiotensin II (P 5 0.51) (data not shown). Together, our in vitro and in vivo data confirm a role for Endog in cardiomyocyte hypertrophy and identify ROS as conserved pro-hypertrophic stimuli in both systems.
Endog has been proposed to be important for apoptotic cell death 8 ; however, this was subsequently disputed 16, 17 , and it was unclear how Endog loss of function was associated with cardiac hypertrophy and dysfunction. To infer the function of ENDOG in the human heart, we carried out genome-wide co-expression network analysis 23 in a large human cardiac expression data set (n 5 210) (see Supplementary  Methods) . ENDOG was identified in a network that was highly enriched for mitochondrial genes (P 5 2 3 10 258 ) and oxidative metabolism processes (P 5 5 3 10 238 ) ( Fig. 3 and Supplementary Tables 2  and 3 ). Taken together, the high levels of Endog expression in metabolically active organs ( Fig. 2a ) and in brown fat ( Supplementary  Fig. 6 ), the unique co-expression of ENDOG with oxidative metabolism genes, and the link to AMPK signalling and ROS production Supplementary Methods) . Low-hanging branches in the dendrogram (top) represent groups of genes (modules) that have a high similarity metric. Modules are shown beneath the dendrogram (centre) and are colour coded. The arrow indicates the module (also boxed) that contains ENDOG. In the heat map of the correlations between expression profiles (bottom), high and low similarities are coloured yellow and red, respectively. b, Weighted gene co-expression network analysis (WGCNA) 23 for the module that contains ENDOG, providing functional annotation through cellular localization by Gene Ontology (GO) classification (Supplementary  Tables 2 and 3 ). Nodes represent genes, and edges represent significant coexpression between genes. The node size is proportional to the relative degree of interconnectivity of each gene within the module. c, Quantitative PCR analysis of Endog expression in cultured cardiomyocytes after infection with adenovirus (ad) expressing green fluorescent protein (GFP) (ad.GFP) or increasing amounts of adenovirus expressing Pgc1a (ad.Pgc1a) (wedge). d, Immunoblotting analysis of Endog expression in ad.Pgc1a-infected cardiomyocytes (top), skeletal muscle of WT mice and transgenic mice expressing Pgc1a under the control of muscle creatine kinase (MCK-Pgc1a) (centre), and hearts of WT and cardiac-specific Pgc1a-deleted mice (Pgc1a DC/DC ) (bottom). e, Endog promoter activity, measured using a luciferase reporter, in HEK293 cells infected with ad.Pgc1a and/or ad.Erra. f, ERR-a ChIP-PCR of two regions of the ENDOG promoter. Red arrows denote primers, and ERRE specifies the location of a consensus ERR response element (1, 304 bases upstream of the transcription start site). The experiment was repeated three times with similar results, and PCR products were quantified by quantitative PCR.
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pointed to an unappreciated effect of Endog in physiological mitochondrial processes.
Peroxisome proliferator activated receptor-c co-activator 1a (PGC1a) is widely recognized as a master regulator of mitochondrial function 24 and activates many target genes that are components of the ENDOG-associatednetwork (Fig.3b )through interaction with oestrogenrelated receptor-a (ERR-a) 9 . Therefore, we tested whether PGC1a also regulates Endog, and we observed robust PGC1a-induced Endog transcript and ENDOG protein expression in cardiomyocytes in vitro (Fig. 3c, d) . We confirmed the effects of varying Pgc1a expression on ENDOG protein expression in vivo using mice that overexpressed Pgc1a under the control of muscle creatine kinase (MCK-Pgc1a) and in mice in which Pgc1a had been deleted specifically in cardiomyocytes (Pgc1a DC/DC ) ( Fig. 3d and Supplementary Methods) . Luciferase studies revealed strong activation of the Endog promoter by PGC1a and ERR-a together (Fig. 3e) , and we confirmed direct binding of ERR-a to the ENDOG promoter by chromatin immunoprecipitation and PCR (ChIP-PCR) in a region containing an ERRA response element (P , 0.001) (Fig. 3f) . These data show that Endog is a direct target of ERR-a and PGC1a, master regulators of mitochondrial and heart function, further implicating Endog in mitochondrial and cardiac biology.
It was apparent that the effects of Endog loss of function on cardiac hypertrophy might be mediated through perturbations of mitochondrial physiology, which we therefore examined. Electron microscopy revealed lipid-like droplets associated with the mitochondria of Endog 2/2 mice, and these droplets were more numerous and larger than those seen in control mice (Fig. 4a, b) . Molecular studies revealed a marked elevation of triglyceride levels in the hearts of Endog 2/2 mice (Fig. 4c ) that manifested as cardiomyocyte steatosis (Fig. 4a and Supplementary Fig. 7 ) but was not associated with variation in the expression levels of fatty acid metabolism or mitochondrial biogenesis genes ( Supplementary Figs 8 and 9 ). Compared with their wild-type littermates, Endog 2/2 mice had impaired mitochondrial respiration and increased ROS production ( Fig. 4f, g) .
To assess for mitochondrial depletion, we examined the ratio of mitochondrial DNA (mtDNA) to genomic DNA and the mitochondrial protein to tissue weight ratios, which were both diminished in the hearts of Endog 2/2 mice (Fig. 4d, e ) in the absence of mtDNA structural variation ( Supplementary Fig. 10 ). This was an intriguing finding given the previously proposed roles for Endog in mtDNA synthesis, processing of polycistronic mtRNA and mitochondrial biogenesis 25, 26 , which had subsequently been discarded based primarily on experiments in Endog-deleted mice 16, 17 . We re-examined a role for ENDOG in mitochondrial biogenesis and demonstrated an increase in mitochondrial mass with chronic ENDOG expression in HEK293 cells (P , 0.01) and with acute Endog overexpression in a cardiomyocytederived cell line (P , 0.001) ( Fig. 4h-k) in the absence of an effect on apoptotic or necrotic cell death ( Supplementary Fig. 11 ). A role for ENDOG in mtDNA biology 25, 26 was supported further by ChIP-PCR experiments that showed direct binding of ENDOG throughout the mtDNA molecule ( Fig. 4l ), as previously demonstrated for mitochondrial transcription factor A (TFAM) 27 , which is a crucial determinant of mtDNA synthesis and repair that when deleted causes eccentric cardiac hypertrophy and heart failure 28 . Supplementary Fig. 7 
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Mitochondria are essential for oxidative metabolism, and mitochondrial dysfunction and/or depletion in the heart causes maladaptive cardiac hypertrophy and cardiac dysfunction associated with increased amounts of ROS and lipotoxicity 4, 5, 28, 29 . Here we identified Endog loss of function as a primary determinant of maladaptive cardiac hypertrophy that is associated with mitochondrial dysfunction and depletion and with marked cardiomyocyte steatosis. The mechanism underlying cardiac hypertrophy that results from impaired mitochondrial function is not limited to a single pathway, but we demonstrated a conserved increase in ROS, which are established hypertrophic stimuli 21, 22 , in Endog loss-of-function models. Our studies resolve some of the uncertainty about the non-apoptotic function of Endog 15-17 and reveal its importance in mitochondrial biology, which has intriguing parallels with the dual roles of apoptosis-inducing factor 30 . We propose that ENDOG, which we show binds to mtDNA, modulates mtDNA synthesis, maintenance and/or transcription, which is consistent with previous hypotheses 25, 26 . Therapeutic targeting of the PGC1A-ERRA axis has been proposed to improve mitochondrial function in cardiac failure 11 , and our studies suggest that regulation of Endog is an important component of this process. We conclude that Endog is a novel determinant of maladaptive cardiac hypertrophy with previously unappreciated mitochondrial functions.
METHODS SUMMARY
Linkage mapping was carried out using microsatellite genotypes in the BN 3 SHR F 2 population. Ex vivo heart weight analysis was performed in the congenic rat strains, which were characterized using in vivo blood pressure telemetry. Comparative haplotype analysis was performed using single nucleotide polymorphism data (Rat Genome Database; http://rgd.mcw.edu/) for all strains used in the QTL mapping studies. Microarray-based expression analysis was conducted as described previously 6, 7 . Cell size and hypertrophy biomarker expression were measured in cardiomyocytes after lentivirus-mediated Endog knockdown. Heart weight, hypertrophic biomarker expression and cardiomyocyte size were measured in Endog 2/2 mice at baseline and after angiotensin-II-induced hypertrophy. Triglyceride abundance, mitochondrial mass and respiratory activity were measured in Endog 2/2 mice as described in the Supplementary Information. Weighted gene co-expression network analysis (WGCNA) 23 was applied to the largest publicly available human heart transcriptome data set. Regulation of Endog by PGC1a was investigated in neonatal cardiomyocytes infected with adenovirus expressing Pgc1a, in MCK-Pgc1a skeletal muscle and in Pgc1a DC/DC heart samples. The association of ERR-a with the ENDOG promoter and the ENDOG-mtDNA interaction were determined using ChIP. The histological analysis and electron microscopy of Endog 2/2 hearts was carried out to study mitochondrial structure and abundance, as well as lipid deposition. Genomic DNA and mtDNA copy number were assessed by quantitative PCR. The mitochondrial abundance in cells was studied by flow cytometry. Full methods are provided in the Supplementary Methods.
